2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5309 Frequency, severity, and clinical impact of cytopenias following bispecific antibody (BsAb) therapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL)

Allison Marie Bock, MD, Maren Campbell, PharmD2, Ruitao Liu3, Xi Qiao, PhD4, Ayushi Chauhan, MD5, Swetha Thiruvengadam, MD6, Lorenzo Falchi, MD7, Sonia Godbole, MD8, Ajay Major, MD, MBA9, Reid W Merryman, MD10, Geoffrey Shouse, DO PhD11, Andrew P. Jallouk, MD, PhD12, Shakthi P. Bhaskar, MD13, Gulrayz Ahmed, MD14, Matthew A. Lunning, DO, FACP15, Amy A. Ayers16, Jessica Allen, MD17, Steven Bair, MD18, Mehdi Hamadani, MD19, Alexey V. Danilov, MD, PhD20, Christopher R. Flowers Jr, MD, MS21, Jennifer L. Crombie, MD22, Alex Francisco Herrera, MD23, Yazeed Sawalha, MD24, Sairah Ahmed, MD25, Gilles Salles I, MD, PhD26, Narendranath Epperla, MD, MS, FACP27
1 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
2 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
3 University of Utah, Salt Lake City, Utah, United States
4 University of Utah, Salt Lake City, Utah, United States
5 MD Anderson Cancer Center, Houston, United States
6 City of Hope, Duarte, United States
7 Memorial Sloan Kettering Cancer Center, New York City, United States
8 The Ohio State University, Columbus, United States
9 University of Colorado, Aurora, United States
10 Dana-Farber Cancer Institute, Boston, United States
11 City of Hope, Duarte, United States
12 Vanderbilt University Medical Center, Nashville, United States
13 The Ohio State University, Columbus, United States
14 Medical College of Wisconsin, Milwaukee, United States
15 University of Nebraska, Omaha, United States
16 MD Anderson Cancer Center, Houston, United States
17 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
18 University of Colorado, Aurora, United States
19 Medical College of Wisconsin, Milwaukee, United States
20 City of Hope, Duarte, United States
21 MD Anderson Cancer Center, Houston, United States
22 Dana-Farber Cancer Institute, Boston, United States
23 City of Hope, Duarte, United States
24 The Ohio State University, Columbus, United States
25 MD Anderson Cancer Center, Houston, United States
26 Memorial Sloan Kettering Cancer Center, New York City, United States
27 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States

Introduction:

Cytopenias are common following BsAb therapy in patients (pts) with R/R FL, as reported in pivotal trials. However, the timing and duration of cytopenias and their association with infections and survival remain poorly defined. Hence, we evaluated the incidence and kinetics of cytopenias following BsAb therapy and their association with infections and survival outcomes in a real-world cohort of R/R FL pts.

Methods:

This is a multicenter retrospective study of adult pts with R/R FL treated with BsAbs outside of a clinical trial between 2022 and 2026 across 10 centers within the Collaborative US Bispecific Consortium (CUBIC). Cytopenias were graded by CTCAE v5.0 grading and considered early if day (D) 0-29 (D30) or late, day 30-89 (D90) and day 90 through 6 mo (6 mo). Severe neutropenia was defined as grade (G) 4 with ANC < 500/uL, severe thrombocytopenia as G3 or greater with platelet count < 50 × 109/L, and severe anemia as G3 with hemoglobin < 8 g/dL. Progression-free survival (PFS) and overall survival (OS) were analyzed using landmark analyses at D30 and D90 to evaluate the association between neutropenia at each respective landmark and subsequent survival outcomes.

Results:

A total of 168 pts with FL were included. BsAb therapy consisted of mosunetuzumab in 85% (n=142), epcoritamab in 14% (n=23), and glofitamab in 2% (n=3); 10% of pts (n=16) received concomitant systemic therapy (CST). Median age was 68 yrs (range 33-101), median number of prior lines of therapy (pLOT) was 3 (range 0-14), 84% had stage III/IV disease (n=134), 50% had a FL International Prognostic Index (FLIPI) score of ≥ 3 (n=73), and 14% (n=23) had received prior CAR-T.

 Overall, any grade neutropenia occurred in 10% of pts (n=17), including G4 in 2% (n=4). During BsAb therapy, any grade neutropenia occurred in 4% (n=6) at D30, with no G4 events. Any-grade neutropenia increased to 6% (n=7) at D90, including 3% (n=3) with G4 neutropenia, and 13% (n=4) at 6 mo, including 3% (n=1) G4 neutropenia. GCSF was administered to 13% (n=22). FLIPI > 3 was significantly associated with D30 neutropenia (p<0.05) and no CST was significantly associated with all grade and severe neutropenia at D90 (p<0.05) compared to BsAb monotherapy. No significant associations were noted between neutropenia (any-grade, severe, early or late) and age, ECOG PS, stage, BsAb type, prior CAR-T, or ≥ 3 pLOT. Severe thrombocytopenia and anemia were uncommon, occurring early in 1% of pts (n=2), with no late severe events. 

Following BsAb initiation, 32% of pts (n=51/161) developed any grade infections, including 7% (n=10/147) with G3+ infections. Infections occurred in 14% (n=23) by D30, 7% (n=11) by D90, 8% (n=13) by 6 mo, and 2% (n=4) >6 mo. Viral infections were most common (18%, n=29), followed by bacterial infections (11%, n=17) with respiratory infections being most common site in 23% (n=37). Recurrent infections occurred in 12% (n=20), while 8% (n=14) required hospitalization. Viral/PJP prophylaxis (ppx) was administered to 48% (n=82) and 18% (n=25/138) received IVIG. Among pts with any severe or non-severe neutropenia, G3+ infections were more frequent (p<0.05) compared to pts with no neutropenia. Among pts with G4 neutropenia, respiratory infection site was more frequent compared to pts with non-severe neutropenia or no neutropenia. There was no significant difference in the frequency, type or timing of any grade or G3+ infections in pts with early or late neutropenia compared to those without neutropenia.

At a median follow up of 12.1 mo (95% CI, 10.1-14.9 mo), non-severe neutropenia was not associated with differences in PFS or OS compared with no neutropenia at D30, and severe neutropenia was not associated with differences in PFS or OS at D90 and across the D0-90 interval compared with non-severe or no neutropenia.

Conclusions:

In this large cohort of pts with FL treated with BsAbs, both early and late severe cytopenias were uncommon. Rates of any-grade neutropenia, and severe cytopenias were less frequent compared to the pivotal trials. Although any grade infections were common and neutropenia was associated with G3+ infections, rates of G3+, and recurrent infections were low.  These findings provide a comprehensive characterization of cytopenias and infectious complications associated with BsAb therapy in routine clinical practice and support the continued use of BsAbs in older pts and those with heavily pretreated R/R FL.

Maren Campbell, PharmD: Xspray - Consultancy (Includes expert testimony)